Evaluating a new imaging agent for cancer detection
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers
This study is testing a new imaging agent for cancer called 18F-FAPI-Biotin to see if it can help doctors find tumors better than current imaging methods.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 5 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06734572 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety, biodistribution, and radiation dosimetry of a novel dual-targeting PET radiotracer called 18F-FAPI-Biotin in patients with various types of cancer. The research aims to compare the imaging efficacy of 18F-FAPI-Biotin with existing PET tracers, 18F-FAPI and 18F-FDG, to assess its potential advantages in detecting tumor lesions. By targeting fibroblast activation protein and biotin, the study seeks to enhance the sensitivity and specificity of cancer imaging. Participants will undergo PET/CT scans to evaluate the pharmacokinetics and dosimetric characteristics of the new tracer.
Who should consider this trial
Good fit: Ideal candidates include patients with various solid tumors who have confirmed histopathological findings.
Not a fit: Patients who are pregnant, lactating, or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cancer imaging techniques, allowing for better diagnosis and treatment planning.
How similar studies have performed: While the approach of using dual-targeting PET tracers is promising, it is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Various solid tumors with available histopathological findings • Signed informed consent Exclusion Criteria: * pregnant or lactational women • who suffered from severe hepatic and renal insufficiency
Where this trial is running
Fuzhou, Fujian
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Principal investigator: Weibing Miao, MD — First Affiliated Hospital of Fujian Medical University
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: +86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.